Radioligand Therapy (RLT) Market Research Report: Industry Analysis and Forecast, 2025–2035

Isotope development is a critical growth engine for the Radioligand Therapy (RLT) Market. Gallium-68 leads diagnostic applications, while Lutetium-177 is rapidly gaining traction for therapeutic use and is projected to generate USD 8.0 billion by 2035. Fluorine-18 remains integral to PET imaging workflows. Technological advances in radiochemistry and novel labeling techniques are expanding treatable cancer indications beyond prostate cancer and neuroendocrine tumors. The convergence of diagnostic and therapeutic capabilities—theranostics—is enabling personalized treatment planning, where patients are first imaged with Gallium-68 PSMA PET and subsequently treated with Lutetium-177 PSMA therapy, optimizing clinical outcomes.

Q1. Which isotope is projected to generate the highest revenue by 2035? A. Lutetium-177 is projected to generate USD 8.0 billion by 2035.

Q2. What role does Gallium-68 play in RLT? A. Gallium-68 is primarily used for diagnostic imaging and PET scans in precision oncology.

Q3. What is theranostics in the context of RLT? A. Theranostics combines diagnostic imaging and targeted therapy using paired radioligands for personalized treatment.